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Human bone marrow contains two major cell types, hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). MSCs
possess self-renewal capacity and pluripotency defined by their ability to differentiate into osteoblasts, chondrocytes,
adipocytes and muscle cells. MSCs are also known to differentiate into neurons and glial cells in vitro, and in vivo following
transplantation into the brain of animal models of neurological disorders including ischemia and intracerebral hemorrhage
(ICH) stroke. In order to obtain sufficient number and homogeneous population of human MSCs, we have clonally isolated
permanent and stable human MSC lines by transfecting primary cell cultures of fetal human bone marrow MSCs with
a retroviral vector encoding v-myc gene. One of the cell lines, HM3.B10 (B10), was found to differentiate into neural cell types
including neural stem cells, neurons, astrocytes and oligodendrocytes in vitro as shown by expression of genetic markers for
neural stem cells (nestin and Musashi1), neurons (neurofilament protein, synapsin and MAP2), astrocytes (glial fibrillary acidic
protein, GFAP) and oligodendrocytes (myelin basic protein, MBP) as determined by RT-PCR assay. In addition, B10 cells were
found to differentiate into neural cell types as shown by immunocytochical demonstration of nestin (for neural stem cells),
neurofilament protein and b-tubulin III (neurons) GFAP (astrocytes), and galactocerebroside (oligodendrocytes). Following
brain transplantation in mouse ICH stroke model, B10 human MSCs integrate into host brain, survive, differentiate into
neurons and astrocytes and induce behavioral improvement in the ICH animals. B10 human MSC cell line is not only a useful
tool for the studies of organogenesis and specifically for the neurogenesis, but also provides a valuable source of cells for cell
therapy studies in animal models of stroke and other neurological disorders.
Citation: Nagai A, Kim WK, Lee HJ, Jeong HS, Kim KS, et al (2007) Multilineage Potential of Stable Human Mesenchymal Stem Cell Line Derived from
Fetal Marrow. PLoS ONE 2(12): e1272. doi:10.1371/journal.pone.0001272
INTRODUCTION
Human bone marrow contains two major cell types, hematopoi-
etic stem cells (HSCs) and mesenchymal stem cells (MSCs). MSCs
possess self-renewal capacity and pluripotency defined by their
ability to differentiate into bone, fat, cartilage and muscle [1–4].
MSCs are also known to differentiate into neurons and glial cells in
vitro and in vivo [5–7].
Two major types of stroke are ischemic stroke and intracerebral
hemorrhage (ICH), and ICH represents at least 15% of all strokes
in the western population [8], while in Asia including China,
Japan and Korea ICH occupies considerably higher proportion at
50–60%[9]. ICH is a lethal stroke type, as mortality approaches
50% and neurological disability in survivors is common. Since
medical therapy against ICH such as mechanical removal of
hematoma, prevention of edema formation by drugs, and
reduction of intracranial pressure, shows only limited effectiveness,
alternative approach is required [10,11].
Previous studies have reported that MSCs engrafted in animal
models of stroke survive and ameliorate neurological deficits in the
animals [12–15], raising the possibility of therapeutic potential of
MSCs for repair of damaged brain in ICH animal models and
patients. However, the studies related to the cellular and molecular
properties of human MSCs run into difficulty in obtaining
sufficient number and homogeneous population of human MSCs,
and primary MSCs can be provided for only a limited time before
they undergo senescence. Generation of sustainable human MSC
clones is necessary to circumvent these problems. Previously we
have isolated clonal human neural stem cell lines that had been
immortalized by a retroviral vector encoding v-myc oncogene[16–
19], and these cells show multipotent differentiation capacity to
differentiate into neurons and glial cells [16–18], ameliorate
neurological deficits in animal models of stroke [20–24], Parkinson
disease [25], Huntington disease [26,27] and lysosomal storage
disease [28] following their transplantation into the brain. Using
a similar procedure, we have generated clonal immortalized
human mesenchymal stem cell lines by transfecting primary cell
cultures of fetal human bone marrow mesenchymal stem cells with
a retroviral vector encoding v-myc oncogene. One of the cell lines,
HM3.B10 (B10), was found to differentiate into glial cells in vitro
and in vivo, and also restore functional deficits in mice with
experimenal ICH following brain transplantation.
METHODS
Primary culture of human bone marrow cells
Bone marrow cells (MSCs) were obtained from human fetal spinal
vertebrae of 12–15 weeks’ gestation. The permission to use
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PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1272embryonic tissues was granted by the Clinical screening committee
for research involving human subjects of the University of British
Columbia. Bone marrow tissues were isolated from the vertebrae
using two scapels and grown in 60 mm culture dishes with
Modified Eagle medium alpha (MEM-a) supplemented with 10%
fetal bovine serum and 25 mg/ml gentamicin (feeding medium).
After 2–3 weeks, cultures reached confluency and MSCs were
passaged further. MSCs used in the present study were cultures at
4th to 11th passage.
Retrovirus-mediated gene transfer
Human MSCs were subjected to retrovirus mediated-transduction
of v-myc by LSNv-myc construct and subsequent cloning. An
amphotropic replication-incompetent retroviral vector encoding v-
myc oncogene (transcribed from mouse leukemia virus LTR plus
neomycin-resistant gene transcribed from a SV40 early promotor)
was used (Figure 1A). This amphotropic vector, LSNv-myc, was
generated in our laboratory using the ecotropic retroviral vector
encoding v-myc (American Type Culture Collection, Manhasset,
VA) to infect PA317 amphotropic packaging cell line. Infection of
human MSCs in 6 well plates was performed twice by the
established procedures [17,19,29]. Briefly, 2 ml of supernatant
(4610
5 CFUs) from the PASK packaging cell line and 8 mg/ml
polybrene (Sigma) were added to target cells in 6 well plates and
incubated for 4 hr at 37uC. The medium was then replaced with
fresh growth medium. Infection was repeated 24 hr later. Seventy-
two hr after the second infection, infected cells were selected with
G418 (250 mg/ml, Sigma) for 7–14 days and large clusters of
clonally derived cells were individually isolated and grown in 6
well plates. Individual clones were generated by limited dilution
Figure 1. Generation of HM3.B10 (B10) immortalized human bone marrow mesenchymal stem cell (MSC) line. (A): The retroviral vector encoding
v-myc used for the generation of B10 immortalized human MSC line from primary culture of human fetal bone marrow cells. The vector has an
internal SV40 promoter (SV40) from which the neomycin-resistant gene (NeoR) is transcribed and translated. The myc oncogene (v-myc) is
transcribed from the LTR (long terminal repeat). (B): Karyotyping analysis of B10 cells revealed the normal human karyotype of 46, XX. (C): Phase
contrast microscopy of primary human MSCs derived from fetal human bone marrow (16 weeks gestation). Bar indicates 20 mm. (D):
Immunofluorescence microscopy of primary human MSCs expressing nestin staining, a cell type specific-marker for neural stem cells. Cell nuclei are
labeled by DAPI. (E): Phase contrast microscopy of B10 human MSC cell line at passage 11. (F): Immunofluorescence microscopy of B10 cells
expressing nestin staining. Bars in (C–F) indicate 20 mm.
doi:10.1371/journal.pone.0001272.g001
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clones were designated as HM3 human MSC cell lines. One of
these clones, HM3.B10 (B10), was subjected to further study.
Fluorescence activated cell sorting
For fluorescence activated cell sorter (FACS), B10 cells were
detached by a brief trypsin treatment and stained sequentially with
immunofluorescence conjugated antibodies, fixed with 2% para-
formaldehyde for 5 min, and then analyzed with flow cytometer
(FACS Vantage, Becton Dickinson). The antibodies utilized for
FACS analysis are shown in Table 1.
Differentiation culture conditions
Adipogenic differentiation of B10 cells was induced by growing the
cells in a 6-well plate in DMEM containing 10% FBS, 5 mg/ml
insulin, 1 mM dexamethasone, 100 nM indomethacin and 0.5 mM
methylisobutylxanthine (Sigma) for 48 h, then cells were incubated
in the same medium without dexamethasone. One week after the
induction, cells were stained with oil-red. To induce osteogenic
differentiation, B10 cells were cultured in DMEM containing
10 mM b-glycerophosphate, 0.2 mM ascrobate-2-phosphate,
10 nM dexamethasone. After 14 days, osteogenic differentiation
was evaluated by alkaline phosphatase staining. For chondrogenic
differentiation, pellets of B10 cell were cultured for 3 weeks in the
presenceoftransforminggrowth factor-b1(T GF b-1) in DM4serum-
free medium (DMEM containing 10 mg/ml human insulin, 10 mg/
ml human transferrin, 3 nM sodium selenite, 5 nM hydrocortisone
and 100 pM triiodothyronine) [30]. This medium was replaced
every 3–4 days for 21 days. Development of chondrogenic
differentiation was determined by staining the pellet with Alcian
blue. For neuronal induction, B10 cells were grown in DMEM
containing 1% FBS and supplementary 100 ng/ml bFGF for 14
days. Induction of neuronal and glial phenotypes in B10 cells was
confirmed by immunostaining with antibodies specific for neurofila-
ment-H, b-tubulin III and glial fibrillary acidic protein (GFAP). In
order to induce neuronal and glial phenotypes in B10 cells, feeding
media containing 1% FBS and various growth factors (bFGF, EGF,
VEGF, NGF, BDNF and CNTF) or modulators (phorbol ester and
forskolin) were tested, and bFGF at 100 ng/ml proved to be most
effective in inducing neuronal phenotype.
Immunocytochemistry
Immunochemical determination of cell type specific markers in
B10 cells was performed as follows: B10 cells were grown on poly-
D-lysine-coated Aclar plastic coverslips (9 mm in diameter) for 3–
14 days, fixed in cold methanol for 10 min at 220uC, air dried,
and incubated with primary antibodies, followed by biotinylated
secondary antibodies and avidin-biotin complex (ABC, Vector,
Burlingame, CA) and visualized with 3-amino-9-ethyl carbazole
(Sigma) chromogen development [29,31]. For immunofluores-
cence studies, cultures were incubated with primary antibodies,
followed by fluorescent secondary antibody (Alexa Fluor 488 anti-
mouse IgG (1:200, Molecular Probe, Eugene, OR) or Alexa Fluor
594 anti-rabbit IgG (1:200) for 1 hr at RT and viewed under an
Olympus laser confocal microscope. Cell type-specific markers
used were neurofilament-L (NF-L), neurofilament-M (NF-M) and
tubulin-b isotype III (b-tubulin III) for neurons, glial fibrillary
acidic protein (GFAP) for astrocytes and cyclic nucleotide
phosphodiestelrase (CNPase) for oligodendrocytes. Mouse mono-
clonal antibodies specific for NF-L, NF-M and tubulin-b III, and
CNPase were obtained from Chemicon (Temecula, CA), and
rabbit anti-GFAP antibody was obtained from DAKO (Carpinteria,
CA). For oil-red staining for adipose cells, cells were fixed with 4%
paraformaldehyde for 10 min, washed with PBS, incubated with
Oil-Red-O (Sigma) for 10 min and counterstained with Mayer
hematoxylin for 3 min. For alkaline phosphatase staining for
osteoblasts, cells were fixed with 4% paraformaldehyde for
10 min, washed with PBS, incubated with fast 5-bromo-4-chloro-
3-indolyl phosphate and nitroblue tetrazolium substrate (Sigma) for
20 min. For Alcian blue staining for chondroblasts, cell pellets were
fixed with 4% paraformaldehyde at 4uCf o r2h ,e m b e d d e di n
paraffin and sections stained with 0.5% Alcian blue solution for
15 min and counterstained with Myer hematoxylin for 1 min.
RT-PCR analysis
RT-PCR was performed with oligonucleotide primers in Table 2.
Sense and antisense primers of each primer pair were set at
a different exon, respectively, to avoid DNA contamination. Total
RNA was extracted using TRIzol reagent (GIBCO-BRL,
Gaithersburg, MD). Complimentary DNA (cDNA) templates
from each sample were prepared from 1 mg of total RNA primed
with oligo dT primers (Pharmacia, Gaithersburg, MD) using
400 units of MMLV reverse transcriptase (Promega, Madison,
WI) followed by 30 PCR amplification cycles (94uC for
30 seconds, annealing at 60uC for 60 seconds, and extension at
72uC for 90 seconds). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a reaction standard. Ten mL of each PCR
product was analyzed by 1.5% agarose gel electrophoresis.
Authentic bands were determined by selective enzyme digestion.
Electrophysiology
B10 cells grown on coverslips for 11–14 days were placed in
a recording chamber on the stage of an inverted microscope
(Eclipse TE2000-S, Nikon, Tokyo, Japan), and membrane
currents were recorded using the whole-cell patch clamp
technique [16]. Patch micropipettes having resistance of 2–
4M V were pulled by a puller (P87, Sutter Instruments, Novato,
CA) from borosilicate glass capillaries (G150T-3, Warner Instru-
ments, CT) and fire-polished using a microgorge (MF-79,
Narishige, Japan). The pipette were filled with an intracellular-
like solution containing (in mM) 140 KCl, 5 NaCl, 1 CaCl2,1 0
HEPES, 5 EGTA, 2 Mg-ATP for the inward Na
+ currents or
outward K
+ currents measurement. The pH was adjusted to 7.3
with KOH and filtered before use. The standard external solution
was comprised of (in mM) 140 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2,1 0
glucose, 10 HEPES. The solutions were adjusted to pH 7.3 with
NaOH. Whole-cell currents were recorded at 22–24uC using
Table 1. Phenotypic analysis of B10 cells with FACS.
......................................................................
Epitope Source of Ab HM3.B10
CD13 Immunotechnology (+)
CD29 (b1-integrin) Becton Dikinson (+)
CD44 (endoglin) Becton Dikinson (+)
CD49b Fujisawa (+)
CD90 (Thy-1) Becton Dikinson (+)
CD166 Becton Dikinson (+)
CD14 Becton Dikinson (2)
CD34 Becton Dikinson (2)
CD45 Becton Dikinson (2)
HLA-DR Immunotechnology (2)
doi:10.1371/journal.pone.0001272.t001
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Foster City, CA) and digitized by a analog-to-digital interface
(Digidata 1320, Axon Instruments). Membrane currents were low-
pass filtered at 2 kHz and sampled at 50 kHz, then stored on the
hard disk of an IBM-compatible computer using pClamp8.2 (Axon
Instruments). For voltage-clamp measurements, B10 cells were
held at 280 mV and depolarized in 10 mV steps between 270
and +40 mV. The neurotransmitters used were GABA (1 mM),
glycine (100 mM), and N-methyl-D-aspartate (100 mM), and the
inhibitors of neurotransmitters were bicuculline (10 mM), strych-
nine (1 mM), and a mix of APV (2 mM) and CNQX (6-cyano-7-
nitroquinoxaline-2,3-dione; 2 mM) respectively. The bathing
solution or the drug-containing solution was applied to the
recording chamber via a gravity-fed perfusion system.
Mouse ICH model
Male ICR mice weighing 20 to 30 g (7 weeks) were used for ICH
model as described previously [21–24]. Mice were anesthetized
with intraperitoneal injections of 1% ketamine (60 mg/kg) and
placed in stereotactic apparatus. A midline incision was made
Table 2. Sequence of PCR Primers.
..................................................................................................................................................
Gene sense antisense
Lipoprotein lipase CTTCTGTTCTAGGGAGAAAGTG TGCTGTGTAGATGAGTCTGATT
Osteopontin GAAGGACAGTTATGAAACGAGT AACATAGACATAACCCTGAAGC
Osteocalcin ATGAGAGCCCTCACACTCCT CAAGGGGAAGAGGAAAGAAG
PTH receptor AACTACTACTGGATTCTGGTGG CTCCAAGATTTCTTGATCTCAG
Syndecan CCTTCACACTCCCCACAC GGCATAGAATTCCTCCTGTTG
Perlecan CATAGAGACCGTCACAGCAAG ATGAACACCACACTGACAACC
Collagen type II ACGGCGAGAAGGGAGAAGTTG GGGGGTCCAGGGTTGCCATTG
Oct-4 AGGAGATATGCAAAGCAGAA AGAGTGGTGACGGAGACAG
Mash1 CCAACTACTCCAACGACTTG GAAAGCACTAAAGATGCAGG
Otx-2 ATGCAGAGGTCCTATCCCATG CTTATAATCCAAGCAATCAGT
ABCG2 CAAAAACTTGCTGGGTAATC ACAGAAACCACACTCTGACC
Nestin CTCTGACCTGTCAGAAGAAT GACGCTGACACTTACAGAAT
Pax-3 GCCAATCAACTGATGGCTTT CATTCGAAGGAATGGTGCTT
Pax-6 GGTCTGTACCAACGATAACATAC CTGATAGGAATATGACTAGGTGTG
Wnt-1 ATGGGGCTCGCTGTT CCCACTCATGCAGGA
NeuroD1 CCGACAGAGCCCAGATGTAGTTCTT GCCCCAGGGTTATGAGACTATCACT
Sox-1 AACCCCAAGATGCACAACTC TAGCCCAGCCGTTGACAT
Sox-2 AGTACAACTCCATGACCAGC TTACTCTCCTCTTTTGCACC
Sox-3 AGAACCCCAAGATGCACAAC CTGCACGAGCGAGTAGGC
Sox-9 TGAAGAAGGAGAGCGAGGAA GGGGCTGGTACTTGTAATCG
Sox-10 AGGAGAAGGAGGTTGACTGT TCCTCAAAGCTACTCTCAGC
NF-L TCCTACTACACCAGCCATGT TCCCCAGCACCTTCAACTTT
NF-M TGGGAAATGGCTCGTCATTT CTTCATGGAAGCGGCCAATT
NF-H CTGGACGCTGAGCTGAGGAA CAGTCACTTCTTCAGTCACT
Synaptophysin CTTCCTGCAGAACAAGTACC CTTAAACACGAACCACAGGT
MAP2 CTCAACAGTTCTATCTCTTCTTCA TCTTCTTGTTTAAAATCCTAACCT
MBP ACACGGGCATCCTTGACTCCATCGG TCCGGAACCAGGTGGGTTTTCAGCG
GFAP GCAGAGATGATGGAGCTCAATGACC GTTTCATCCTGGAGCTTCTGCCTCA
NGF TCATCATCCCATCCCATCTTCCAC CACAGCCTTCCTGCTGAGCACAC
BDNF ATGACCATCCTTTTCCTTACT CTATCTTCCCCTTTTAATGGT
NT3 ATGTCCATCTTGTTTTATGTGA TCATGTTCTTCCGATTTTTC
GDNF ATGAAGTTATGGGATGTCGT TTAGCGGAATGCTTTCTTAG
CNTF ATGGCTTTCACAGAGCATT AACTGCTACATTTTCTTGTTGTT
bFGF GGGTGGAGATGTAGAAGATG TTTATACTGCCCAGTTCGTT
IGF-1 AAATCAGCAGTCTTCCAACCCA CTTCTGGGTCTTGGGCATGT
HGF AGGAGAAGGCTACAGGGGCAC TTTTTGCCATTCCCACGATAA
VEGF GAAGTGGTGAAGTTCATGGATGTC CGATCGTTCTGTATCAGTCTTTCC
TGFb-1 ACCTGCAAGACTATCGACAT TAGTACACGATGGGCAGC
c-kit TATACAACCCTGGCATTATGTCC TGCGAAGGAGGCTAAACCTA
GAPDH CATGACCACAGTCCATGCCATCACT TGAGGTCCACCACCCTGTTGCTGTA
doi:10.1371/journal.pone.0001272.t002
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Human Mesenchymal Stem Cells
PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1272through the scalp to expose the skull and an injection was made
sterotaxically into the striatum with a 10 ml Hamilton syringe at
the following coordinates: 0.1 mm anterior and 2.0 mm right
lateral to the bregma and 4.0 mm ventral to the cortical surface.
Core animal temperature was maintained at 37uC during this
time. The control group (n=5) received a 0.5 ml injection of saline
alone and the experimental group (n=14) received a 0.5 ml
injection of saline with 0.075 U of collagenase (type VII, Sigma).
The infusion rate for both groups was 0.5 ml/min seconds and
once the infusion was complete, the syringe was left in place for
5 minutes. The mice were allowed to recover from surgery in
a warm environment for 3 hours. All animal experimental
procedures were approved by the Gachon University Animal
Care Committee.
Brain transplantation
In order to detect the grafted cells in host brain, donor cells were
infected by adenovirus mediated LacZ gene in vitro at 100 MOI
(PU/cell) before 24 hr transplantation. Experimental groups are
group 1 (control): injection of PBS (2 ml, n=4); group 2:
transplantation of primary MSCs (2610
5/2 ml, n=7); and group
3: transplantation of B10 cells (2610
5/2 ml, n=7). At 7 days after
ICH, 2610
5 cells (primary human MSCs or B10 cells) in a total
fluid volume of 2 ml were transplanted into ipsillateral striatum,
2 mm cranial to the hemorrhagic lesion, calculated from bregma:
0.1 mm anterior and 2.0 mm right lateral to the bregma and
2.0 mm ventral to the cortical surface.
Behavioral test
Motor function was determined using a rotarod test. In this
procedure, animals were placed on the center of rotating axle and
the time period the animal remained on the axle was measured.
The speed was slowly increased from 4 to 40 rpm with in a period
of 2 min 30 seconds. The animals were trained 1 week before
administration of collagenase and daily, for a period of 7 days,
thereafter.
Histological examination
Two and six weeks following brain transplantation, the animals
were anestherized and perfused with heparinized saline followed
by 4% prarformaldehyde in 0.1 M phosphate buffer (pH 7.4).
Three sections through the needle entry site, 1.0 mm anterior and
1.0 mm posterior to plane were Nissl stained to analyze the
hemisphere area. The total hemispheric areas of each section were
traced and measured with an image analysis system (Image-Pro
Plus, Media Cybernetics, Silver Spring, MD). The morphometric
analyses involved computer-assisted hand delineation of the area
of the striatum, cerebral cortex, and ventricle, as well as the whole
hemisphere. Serial coronal sections (30 mm) throughout the
striatum were cut on a cryostat. b-galactosidase (b-gal) protein
expression was detected in grafted MSCs in vivo, incubating in
enzymatic X-gal solution (5 mM potassium ferricyanide, 5 mM
potassium ferrocyanide, 40 mg/mL X-gal in dimethylformamide)
for 4 hr at 37uC. All chemicals were purchased from Sigma. The
differentiation of grafted MSCs into neural cells was determined
by double-labeling immunofluorescence microscopy. Free-floating
sections were briefly quenched with 3% H2O2 in PBS for 10 min.
Sections were incubated in Tris-buffered saline (TBS) containing
5% normal goat serum and 0.3% Triton X-100 for 30 min at RT
and then incubated overnight with the following primary antibody
mixtures; anti-b-galactosidase (b-gal, 1:300, Sigma)/anti-tubulin-
b isotype III (1:500, Sigma), anti- b-gal/anti-neurofilament (NF,
1:100, Zymed) and anti- b-gal/anti-glial fibrillary acidic protein
(GFAP, 1:500, DAKO). Sections were rinsed with TBS and
incubated with the fluorescent secondary antibodies mixture of
Alexa Fluor 488 anti-mouse IgM (1:200, Molecular Probe), Alexa
Fluor 594 anti-mouse IgG (1:200) and Alexa Fluor 594 anti-rabbit
IgG (1:200) for 1 hr at RT.
ELISA assay for in vitro production of human NGF
and BDNF
To examine in vitro levels of NGF and BDNF production,
primary MSCs and B10 cells were grown in serum-containing
medium (10% FBS) for 48 hr. The spent media were collected and
stored at 280uC. MSCs and B10 cells were harvested after a brief
incubation in PBS containing 0.25% trypsin and 1 mM EDTA at
37uC for 4 min. The cells were lysed in RIPA buffer (150 mM
NaCl, 1% Nonidet P-40, 0.5% deoxycholic acid, 0.1% SDS,
50 mM Tris, pH 8.0) containing protease inhibitors, centrifuged
(10,000g) for 10 min, and the supernatants were used for the assay.
Protein concentrations were determined with Bradford protein
assay (Biorad) with bovine serum albumin as a standard [32].
Production of NGF and BDNF in culture supernatants and cell
lysates was determined by using ELISA kits specific for human b-
NGF (R&D Systems, Minneapolis, MN) or human BDNF
(Promega, Madison, WI).
BDNF ELISA assay in brain sections
Production of NGF and BDNF in culture supernatants and brain
homogenates was determined by using ELISA kits specific for
human a-NGF (R&D Systems) or human BDNF (Promega).
Experimental rats, three groups of 7 each (total n=21) at 2, 4 and
6 weeks post-transplantation, were anesthetized, decapitated and
the brains were removed. Brains were cut in 2 mm coronal
sections. Two-millimeter diameter punches centered on each side
(ipsilateral and contralateral of grafts) of the neostriatum and
adjoining cortex were taken according to the rat brain atlas. Seven
samples were collected from both the ipsilateral and contralateral
sides. The collected samples were homogenized with lysis buffer
(137 mM NaCl, 20 mM Tris, pH 8.0, 1% Nonidet P-40, 10%
glycerol, 1 mM PMSF, 10 mg/ml aprotinin, 1 mg/ml leupeptin
and 0.5 mM sodium vanadate), centrifuged (14,000g) for 30 min
and the supernatants stored at at 270uC until use. Protein
concentrations were determined with Bradford protein assay
(Biorad) with bovine serum albumin as a standard [32]. Levels of
BDNF in tissue lysates were determined by using an ELISA kit
specific for human BDNF.
Stereological cell counts
Total number of LacZ-positve B10 cells in the brain sections from
ICH animals was determined by stereological estimation. The
sections used for counting covered the entire striatum with
hemorrhage lesion and overlying cortex. This generally yielded six
or seven sections in a series. Sampling was done using the
Computer-assisted stereological toolbox system (Olympus Den-
mark A/S, Ballerup, Denmark), using an Olympus BX51
microscope, a motorized microscope stage (Prior Scientific,
Rockland, MA) run by an IBM-compatible computer, and
a microcator (ND 281B, Heidenhain, Schaumburg, IL) connected
to the stage and feeding the computer with the distance
information in the z-axis. The counting areas were delineated
ata 1.256objective and generatedcounting areas of 1506150 mm.
A counting frame (1612 mm
2) was placed randomly on the first
counting area and systemically moved through all counting areas
until the entire delineated area was sampled. Actual counting was
performed using a 1006oil objective. Guard volumes (4 mm from
Human Mesenchymal Stem Cells
PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1272thetop and 4.6 mm from the bottom of the section) were excluded
from both surfaces to avoid the problem of lost caps, and only the
profiles that came into focus within the counting volume (witha
depth of 10 mm) were counted. The estimate of the total number
of Human nuclear antigen (HuNu)-positive B10 cells was
calculated according to the optical fractionator formula [33].
Statistical analysis
Data are presented as means6SEM. The statistical significance
between group comparisons for morphological and behavioral
data was determined by one-way ANOVA test. P values ,0.05
were considered to be statistically significant.
RESULTS
Generation of immortalized human mesenchymal
stem cell lines
Primary MSCs derived from human fetal bone marrow were
transfected with a retroviral vector encoding v-myc oncogene
(Figure 1A), and clones of immortalized human bone marrow
MSCs were generated (see Methods). Several stable clones of
immortalized MSCs were isolated after two rounds of cloning and
were expanded further. Twelve human MSC cell lines were
isolated and one of the clones, HM3.B10 (B10) was used in the
further analysis. B10 cells expressed v-myc oncogene as de-
termined by RT-PCR and carried 46, XX normal human
karyotype as shown by a cytogenetical analysis (Figure 1B). They
are adherent fibroblast-like cells morphologically similar to
primary human MSCs (Figures 1C and D). More than 65% of
B10 cells are nestin-positive compared to 12% in primary human
MSCs. Doubling time of B10 cells was determined to be 36 hr.
FACS analysis and pluripotent capability of B10 cells
FACS analysis of B10 cells demonstrated that more than 95% of
the cells express MSC-specific cell type markers including CD13,
CD29 (integrin-b1), CD44 (endoglin), CD49b, CD90 (Thy-1) and
CD166, but did not express cell type-specific markers for
hematopoietic stem cell (HSC) including CD14, CD34, CD45
and HLA-DR (Figure 2A and Table 1). The phenotypes remained
unchanged for more than 40 cell doublings.
To determine whether B10 cells are pluripotent and able to
differentiate into various celltypes invitro, B10 cells were cultured in
selection media as previously described for human embryonic stem
cells [34]. After 7 days of culture in adipogenic culture medium,
more than 80% of B10 cells differentiated into lipid-laden cells that
stained with oil-red. After 14 days of culture in osteogenic medium,
B10 cells differentiated into osteoblasts, which were confirmed by
strong alkaline phosphatase staining. Differentiation of B10 cells into
chondroblasts was determined by staining the cell pellets with Alcian
blue which identifies proteoglycan extracellular matrix, specific
components of cartilage tissues (Figures 2B–D). Differentiation of
B10 cells into adipocytes, osteoblasts and chondroblasts was also
confirmed by RT-PCR analysis (Figures 2B–D). As in primary
human MSCs [3,35], differentiated B10 cells expressed markers for
adipocytes, osteoblasts or chondrocytes following culture under the
appropriate differentiation-inducing conditions [36].
Genetic expression of primary human MSCs and B10
cells
We examined expression of the genes involved in neural
differentiation of primary human MSCs and B10 cells
(Figure 3A). Both primary MSCs and B10 cells express Oct-4,
which is a cell type-specific marker for the pluripotent stem cells
[37] and B10 cells expressed ABCG2 [38] as a novel stem cell
marker, nestin [39] and Musashi1 [40], both cell type-specific
markers for neural stem cells before and after bFGF treatment
(Figure 3).
The bHLH transcription factors investigated in neuronal
differentiation included Otx2, Pax3, Pax6, Wnt1, Hash1 and
NeuroD1. Expression levels of Pax3, which is involved in the brain
regionalizaion and establishment of dorso-ventral polarity of the
spinal cord during early neurogenesis [41] were increased in both
primary human MSCs and B10 cells following bFGF treatment of
2 weeks. Wnt1 expression [42] in both primary MSCs and B10
cells increased markedly after bFGF treatment. Expression of
Mash1 [43,44], Otx-2 [45] and Pax6 [46], other transcription
factors crucial during the early phase of neurogenesis was
demonstrated in control primary human MSCs and B10 cells,
and expression levels of these transcription factors stayed steady
after bFGF treatment. Expression of NeuroD1, which is expressed
in subsets of CNS neurons during terminal differentiation[47], was
demonstrated after induction by bFGF, indicating that the
transcription factor NeuroD1 participates closely in trans-differ-
entiation of MSCs into neurons. Additionally, we investigated
expression of Sox proteins, which are important in cell fate
determination of progenitor cells if they become neurons or glial
cells [48]. Sox1, Sox2 or Sox3 maintain a stem cell-like state
[49,50], and Sox9 alters the potential of stem cells from
neurogenic to gliogenic [51], whereas Sox10 is essential for
terminal oligodendrocyte differentiation [52]. Expression levels of
Sox2 and Sox3 decreased in especially B10 cells following bFGF
treatment of 2 weeks. Low molecular weight neurofilament protein
(NF-L), found in young immature neurons, increased considerably
after 2 weeks of bFGF treatment and expression of mature NF
forms, NF-M and NF-H, appeared after bFGF treatment.
Genetical analysis also showed increased expression of additional
neuronal cell type-specific markers, synaptophysin and MAP2.
Expression of cell type-specific marker for glial cells, GFAP for
astrocytes, was found in primary human MSCs and B10 cells
regardless of the status of bFGF treatment. Expression of MBP for
oligodendrocytes was found in control primary MSCs but an
increase in its expression was found following the bFGF treatment,
and in B10 cells MBP expression was demonstrated only after the
bFGF treatment. Both primary MSCs and B10 cells expressed
ABCG2 [38] as a novel stem cell marker, nestin [39] and
Musashi1 [40] both cell type-specific markers for neural stem cells
(Figure 3A) before and after bFGF treatment.
Neural differentiation of B10 cells in vitro
Less than 20% of B10 cells was immunoreactive for neuronal
markers, b–tubulin III, NF-L or NF-M when they were grown in
regular feeding medium in the absence of bFGF supplementation,
while treatment with bFGF for 2 weeks, most of B10 cells showed
bipolar or multipolar morphology with branched processes, and
the proportion of B10 cells expressing cell type sepcific markers
increases considerably (Fig. 4A). B10 cells expressing b-tubulin III
increased from 18.161.4% in the control to 62.264.1%, NF-L
from 11.860.6% to 42.861.3%, NF-M from 0 to 22.661.1% and
NF-H from 0 to 1.260.3% (Figure 4C). Less than 2–4% of all B10
cells differentiated into GFAP-expressing astrocytes in vitro
(Figure 4A). Following treatment with bFGF, a larger number of
NF-positive neurons were found in cultures as compared with that
of GFAP-positive astrocytes (Fig. 4B). In the RT-PCR analysis,
B10 cells expressed MBP, a cell type specific marker for
oligodendrocytes (Fig. 3A), and in immunocytochemical investi-
gation a small number of B10 cells expressing oligodendrocyte
specific markers such as galactocerebroside was found in culture
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modulator/inducer of neuronal differentiation from the undiffer-
entiated and uncommitted MSCs.
Generation of sodium current in B10 cells after basic
FGF treatment
Electrophysiological recordings from B10 MSCs treated with
bFGF for 11–14 days were examined with whole-cell voltage
clamp (Figure 5). More than 50% (11 of 20 cells examined) of B10
cells grown for 11–14 days in the presence of bFGF expressed
sodium currents (Figure 5A), while control B10 cells grown in the
absence of bFGF were quiescent and exhibited virtually no sodium
current (n=12). In addition, the sodium currents were blocked
by100 nM tetrodotoxin, and then sodium current reappeared
upon washing out tetrodotoxin (Figure 5B). Concomitant with
sodium current induction, B10 cells grown with bFGF showed
sustained outward currents of a several hundred pA up to 1 nA.
These currents showed a voltage-dependence and kinetics
characteristics for delayed rectifier K+ channels. Positive responses
Figure 2. Charactrization and Differentiation of B10 cells carrying phenotypes of human MSCs. (A): B10 cells were labeled with FITC-coupled
antibodies specific for CD24, CD29, CD34, CD44, CD45, CD166 or immunoglobulin isotype control antibodies. Surface phenotype was analysed by
FACS. Open histograms are for control immunoglobulins and colored histograms are for specific antibodies. MSC markers, CD29, CD44 and CD166 are
expressed in B10 cells while hematopoietic stem cell markers, CD14, CD34 and CD45 are not. (B)–(D): B10 cells were cultured for 2 weeks in the
selection media specifically designed for adipogenic, osteogenic or chondrogenic differentiation. (B), adipogenic differentiation is shown with oil red
O staining and RT-PCR analysis for lipoprotein lipase; (C): Osteogenic differentiation is shown with alkaline phosphatase staining and RT-PCR analysis
for osteopontin, osteocalcin and PTH receptor; (D): Chondrogenic differentiation is detected with alcian blue staining and RT-PCR analysis for
syndecan, perlecan and type II collagen. Bars indicate 50 mm.
doi:10.1371/journal.pone.0001272.g002
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(1 mM GABA, 100 mM glycine, and 100 mM N-methyl-D-
aspartate) were subsequently recorded under 280 mV of holding
potential (n=6 for each neurotransmitters) (Figure 5C). All
neurotransmitters evoked inward currents in more than 50% of
B10 cells, and neurotransmitter-elicited currents were reversibly
blocked by specific antagonists of these receptors: bicuculline
(10 mM), strychnine (1 mM), and mix of APV (2 mM) and CNQX
(2 mM), respectively. The neurotransmitter-evoked currents were
mediated by their respective ionotropic receptors- GABAA
receptor, glycine receptor, and NMDA/AMPA/KA receptors.
B10 cells migrate to hemorrhagic lesion, corpus
callosum and hippocampus in ICH model
Expansion of lateral ventricle by fusion with hematoma cavity
appeared 2–3 weeks after ICH stroke. Primary MSCs and B10
cells labeled with adenovirus-LacZ were transplanted in the cortex
overlying hemorrhage core along the anterior-posterior axis of the
ipsilateral striatum 7 days after ICH stroke (Figure 6A). At 2 weeks
post-transplantation, brain sections were processed for b-gal
staining to identify the transplanted cells and injection tracts of
the transplants were clearly visible and most of the LacZ-positive
B10 cells migrated from the original injection sites and localized at
the boundary of lesion cavity which was fused with dilated lateral
ventricles (Figures 6B–E). In addition, a large number of LacZ-
positive B10 cells was found in the corpus callosum migrating
toward contralateral hemisphere (Figures 6B and 6E). Identical
results were obtained with transplantation studies with primary
human MSCs in ICH rats (data not shown).
Transplanted B10 cells in ICH brain express neural
cell-specific markers
Two weeks after ipsilateral cortical transplantion, a large number
of B10 cells surrounding the hemorrhage core expressed neuronal
markers, b-tubulin III and neurofilament proteins (NF)
(Figures 7A–C) and a smaller number of b-gal-positive B10 cells
expressed GFAP, a specific marker for astrocytes (Figure 7D). We
also found b-gal-positive B10 cells to the other brain sites including
corpus callosum and hippocampus at pyramidal layer of CA2 and
CA3 (Figure 8A). At 6 weeks post-transplantation, the majority of
b-gal-positive B10 cells located in the lesion sites or vicinity
expressed NF indicating that a major population of grafted B10
cells differentiates into neurons with elapsed time of 3–4 weeks
(Figures 8B–D). None of b-gal-positive B10 cells was found to
express CNPase immunoreaction, a specific cell type marker for
oligodendrocytes (data not shown). At two weeks and 6 weeks post-
transplantation, a considerable number of LacZ-positive/b-gal-
positive B10 cells were found in corpus callosum and hippocampus
mostly expressing neurofilament phenotype.
Recovery of behavioral deficits in ICH model by B10
cell transplantation
Motor performance of ICH animals was determined by the
rotarod test in animals receiving PBS, animals transplanted with
primary human MSCs or B10 cells (Figure 9). There is a highly
significant difference between B10-injected and PBS-injected mice
in two-way ANOVA (F=50.32, P,0.0001). While no behavioral
recovery was noted in PBS injected control animals, ICH mice
grafted with B10 cells showed a significant improvement in motor
performance from 8 days post-transplantation and the improve-
ment lasted for up to 7 weeks post-transplantation as compared
with controls by one-way ANOVA (8 days p=0.041, 14 days
p=0.004, 21 days p=0.002, 28 days p=0.007, 35 days p=0.026,
42 days p=0.001, 49 days p=0.040). Behavioral improvement
was also noted in ICH mice grafted with primary human MSCs (8
days p=0.005, 14 days p=0.022, 21 days p=0.001, 28 days
p=0.040, 35 days p=0.046, 42 days p=0.012, 49 days
p=0.011). Significant difference of recovery by transplantation
was detected between human MSCs and B10 cells (p=0.016) only
on 8 days post-transplantation.
Figure 3. Neuronal phenotype and neuronal differentiation of B10
cells. Gene expression of stem cell markers and neuronal markers was
examined by RT-PCR. B10 cells reproduce genetic features of primary
human bone marrow MSCs by expressing ABCG2 and Oct-4 as general
stem cell markers, Mash 1 and Otx 2 as neurogenic bHLH genes, nestin
as a cell type specific marker for neural stem cells, and low-molecular
weight neurofilament protein (NF-L), intermediate molecular weight NF
(NF-M) and high molecular weight NF (NF-H) as specific markers for
neurons. B10 cells were grown in medium containing basic FGF for 2
weeks, In these conditions, B10 cells were demonstrated to differentiate
into neurons.
doi:10.1371/journal.pone.0001272.g003
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Production of cytokines and growth factors by B10 cells was
determined by RT-PCR. As in primary human MSCs, B10 cells
express high levels of NGF, BDNF, CNTF, GDNF, bFGF, IGF-I,
HGF and VEGF (Figure 10). It is interesting to note that the
message for NT3 demonstrated in primary MSCs is not detected
in B10 cells. In addition to growth factors, the RT-PCR study has
demonstrated that both primary human MSCs and B10 cells
express mRNA for VEGFR, CXCR4 and c-kit, cellular receptors
known for close involvement in cellular migration (Figure 10).
Figure 4. Neuronal phenotype and neuronal differentiation of B10 cells. (A): B10 cells in culture were induced to differentiate into neurons in
serum-containing medium supplemented with 100 ng/ml basic FGF for 2 weeks and then processed for nestin (for neural stem cells), b-tubulin III, NF-
L, NF-M and NF-H (for neurons), GFAP (for astrocytes) and galactocerebroside (for oligodendrocytes). Bar inciates 20 mm. (B) Two color
Immunofluorescence microscopy demonstarating pluripotential differentiation of B10 cells into neurons (as shown by NF-L/green staining) and
astrocytes (GFAP/red). B10 cells were grown in serum-containing medium supplemented with basic FGF for 2 weeks. (C) Percentage of neural cells
immunoreaction-positive for b-tubulin III, NF-L, NF-M and NF-H is determined in the B10 cells treated with 100 ng/ml bFGF and the controls (in the
absence of bFGF). Cell number was determined in 5 fields of low magnification. Error bars=SEM.
doi:10.1371/journal.pone.0001272.g004
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SDF-1/CXCR4 and VEGF/VEGFR are important in the
migration of MSCs to the sites of ICH brain damage and also
to corpus callosum and hippocampus. ELISA analyses indicated
that the levels of human BDNF released by B10 cells in vitro were
8.1860.04 ng/10
6 cells/day (mean6SEM) in the spent medium
of B10 culture of 24 hr, which were five times higher than those
from human primary MSCs (1.5360.31 ng/10
6 cells/day,
p,0.001) (Figure 11A). In addition to BDNF, levels of human
NGF were determined by an ELISA kit specific for human NGF
in the culture supernatants of B10 cells and primary MSCs
(Figure 11B). The levels of NGF are very high in both B10 cells
and primary MSCs (388.166.6 vs 292.0623.2 pg/10
6 cells/day,
p,0.01). B10 cells secrete 40% higher level of NGF into the
culture medium.
We also examined the levels of human BDNF in ICH brain
sections 2, 4 and 6 weeks post-transplantation (Figure 11C). BDNF
levels at 2, 4 and 6 weeks post-transplantation in the brain sections
of B10-transplanted loci were 9.2561.00 pg/mg protein (2 wks),
13.1260.67 pg/mg protein (4 wks), and 8.6360.63 pg/mg pro-
tein (6 wks), while production of human BDNF in the brain
sections of PBS-injected mice was below the detectable level of the
ELISA assay. Increased BDNF levels found in the transplanted
ICH brain sections of 6 weeks post-operation indicate that a large
number of implanted B10 cells survived and released substantial
amount of human BDNF even after 6 weeks of transplantation.
Next we examined the BDNF levels in ipsilateral (graft side) and
contralateral sides (nongraft side) of brain sections from both B10-
transplanted and PBS-injected mice (Figure 11D). BDNF levels in
the ipsilateral (B10 graft side) brain sections were 9.2561.00 pg/
Figure 5. Electrophysiology of B10 cells demonstrating neuronal characteristics. (A): Voltage-gated channel activation in B10 cells following
treatment with 100 ng/ml bFGF for 11–14 days. The holding potential was 280 mV and depolarizing steps were applied from 280 mV to +40 mV in
10 mV increments. (B): Na+ currents were activated from a depolarizing step of 240 mV and blocked reversibly by 100 nM tetrodotoxin (TTX). B10
cells grown with bFGF showed sustained outward currents as well. These currents showed a voltage-dependence and kinetics characteristics for
delayed rectifier K+ channels. (C): Neurotransmitter-elicited currents. Application of 1 mM GABA, 100 mM glycine, or 100 mM glutamate resulted in
inward currents in the presence or absence of specific antagonists, bicuculline (10 mM), strychnine (1 mM) or APV (200 mM), respectively.
doi:10.1371/journal.pone.0001272.g005
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8.6360.63 pg/ml at 6 weeks. BDNF levels in the contralateral
side (non-grafted side) of brain sections registered as
1.0060.04 pg/mg protein at 2 weeks, 2.5960.30 pg/mg protein
at 4 weeks and 1.9460.08 pg/ml at 6 weeks. Low levels of human
BDNF detected in the contralateral sides of the brain are
attributed to a small number of b-gal/BDNF double-positive
B10 cells which migrate to the opposite side of the brain via corpus
callosum (see Figure 6). BDNF levels in both ipsilateral and
contralateral brain sections of PBS-injected mice were below the
detectable level of the ELISA assay. In support of B10 cells’
capacity to produce BDNF in high levels in the brain, a large
number of transplanted B10 cells showing b-gal/BDNF-double
positive reaction were found in the lesion sites. Smaller number of
BDNF-expressing B10 cells was also found in corpus callosum and
hippocampus (data not shown).
Survival of transplanted B10 cells in vivo
At 7 days after ICH, 2610
5 B10 cells in a total fluid volume of 2 ml
were transplanted into ipsilateral cortex, 2 mm cranial to the
hemorrhagic lesion. Total number of LacZ-positive B10 cells in
the brain sections from ICH animals was determined by
stereological analysis at 2 weeks and 6-weeks post-transplantation.
The results indicate that cell survival at 2 weeks post-transplatation
is 83,10061140 cells (41.661.7% of the initial population of
200,000 cells) and at 6 weeks the number is 4034062850 cells
(20.262.5% of the initial population of 200,000 cells). Although
number of B10 cells transplanted was 200,000, the cell count of
live cells immediately prior to transplantation (by trypan blue
exclusion test) indicated that actual number of live cells was 80%
(160,000 cells). It is necessary to remove cells from culture dishes
by trypsin treatment for the preparation of cells for transplantation
and this procedure damages cells. From this figure, the results of
Figure 6. Survival of B10 cells transplanted on the area overlying intracerebral hemorrhage lesion in adult mouse brain. (A): Eight days after
lesioning by injection of collagenase, B10 cells were transplanted. Two weeks after transplantation, an extensive migration of B10 cells was identified.
(B): Two weeks post-operation, LacZ-positive B10 cells were noted migrating away from the injection track and located along the hemorrhage
borders and also into contralateral hemisphere via corpus callosum. (C)–(E): Higher magnification of areas identified in (B) indicating a good survival
and long-distance migration of LacZ-positive B10 cells from the injection site. Bar in (B) indicates 0.5 mm, and bars in (C)–(E) are 100 mm.
doi:10.1371/journal.pone.0001272.g006
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animals could be 51.9% at 2 weeks post-transplantation and
25.2% at 6 weeks. Further study is necessary to investigate a long-
term follow-up for the period of 6 months to one year to determine
the fate of grafted cells and such a study is underway in our
laboratory.
DISCUSSION
In the present study, we report the generation of permanent, stable
human mesenchymal stem cell (MSC) lines with properties of self-
renewal and pluripotency. B10 immortalized human MSC line is
capable of differentiation into fat, bone and cartilage and also into
neurons and glial cells in vitro and in vivo. Following transplantation
into the brain of mouse intracerebral hemorrhage stroke (ICH)
model, B10 cells survive, differentiate into neurons and astrocytes
and induce functional improvement in these animals. B10 human
MSC line was established by transfecting primary cultures of
human bone marrow MSCs with a retroviral vector encoding v-
myc. The phenotypic expression of B10 is consistent over culture
passages and is in accordance with the phenotypes of primary
human MSCs as previously reported [3,35,53]. Thus B10 cells
express MSC-specific cell type markers including CD13, CD29
(integrin-b1), CD44 (endoglin), CD49b, CD90 (Thy-1) and
CD166 (Figure 2A and Table 1).
The present study in immortalization and cloning of human
MSCs into stable permanent cell lines represent our attempt to
overcome some of the limitations of primary cultures of MSCs and
provide a potentially significant experimental model for bio-
Figure 7. B10 cells labeled by b-galactosidase (b-gal) transplanted into the cortex overlying the intracerebral hemorrhage (ICH) lesion are found
to differentiate into neurons and astrocytes. Two weeks post-transplantation at the lesion sites. In vivo differentiation of b-gal-positive B10 cells
into neurons was shown by b-tubulin III (A and B), and neurofilament (C) and into astrocytes as shown by GFAP (D) staining. Bar indicates 50 mm.
doi:10.1371/journal.pone.0001272.g007
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MSCs isolated from fetal bone marrow for more than 3 years and
found out that the primary human MSCs do not remain in
a continuous proliferative state in serum free conditions (with
addition of bFGF and EGF), and after a finite number of mitoses
(up to 20), they cease to divide and differentiate. In order to
maintain them in a proliferative state, we have transduced primary
human MSCs with the retroviral vector encoding immortalizing
gene v-myc. Stable immortalized cell lines of human MSC as
described in the present study should provide unlimited number of
homogenous cells derived from a single stem cell and facilitate
follow up of progeny of the same stem cell for prolonged period,
over many generations. When differences in behaviors are
observed for different stem cells in different miniwells, one cannot
discern whether these represent stochastic changes, or are the
product of subtle differences in microenvironmental signals, or
reflect a fundamental heterogeneity of the stem cell population.
Immortalized stem cell line derived from a single cell can
circumvent these problems and produces a clear-cut outcome.
There is a concern about the use of oncogenes for generation of
immortalized stem cell lines, as the oncogene in question might
cause tumor/ectopic formation if cells proliferate indefinitely in
the brain over time following transplantation. Although we did not
find tumor formation in vivo in animals following brain trans-
plantation of B10 human MSCs in the present study, we do not
plan or project clinical trials in patients using the B10 human
MSCs. There is, however, an alternative approach to circumvent
this concern. We have recently generated immortalized human
Figure 8. B10 cells labeled by b-gal differentiate into neurofilament-positive neurons in the striatal hemorrhage lesion site but also in corpus
callosum (CC) and hippocampus indicating that the B10 cells are capable of an extensive migration. Six weeks post-transplantation. (A): LacZ (b-
gal)-positive B10 cells are found migrating into the pyramidal cell layer of hippocampus. Bar indicates 100 mm. (B)–(D): b-galactosidase-positive B10
cells differentiate into neurofilament (NF)-positive neurons in hippocampus in the lesion side (B), in the boundary of striatal lesion (C) and corpus
callosum (D) at 6 weeks post-transplantation. Bar indicates 100 mm.
doi:10.1371/journal.pone.0001272.g008
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transplantation as shown by rotarod test. Fuctional improvement in
mouse ICH model following transplantation of clonal B10 cells, primary
human MSCs and PBS control as determined by rotarod test. Error
bar=SEM. *p,0.05 compared to PBS control. **p,0.05 between B10
cells and primary human MSCs.
doi:10.1371/journal.pone.0001272.g009
Figure 10. Expression of neurotrophic factors in B10 cells by RT-PCR
Gene expression of neurotrophic factors and cytokine receptors
(involved in cellular migration of B10 cells) was analyzed by RT-PCR
in primary human MSCs and B10 cells. B10 cells express genes for
neurotrophic factors including NGF, BDNF, CNTF, GDNF, bFGF, IGF, HGF
and VEGF. In addition, receptors for cytokines known for induction of
cell migration, VEGFR1, CXCR4 and c-kit are expressed by B10 cells.
doi:10.1371/journal.pone.0001272.g010
Figure 11. Expression of neurotrophic factors in B10 cells in vitro and in vivo. (A): ELISA assay for human BDNF demonstrates that B10 cells secrete
BDNF into culture medium approximately 5 times over primary MSCs. Error bar=SEM. *p,0.001 (B): ELISA assay for human NGF showed that both
B10 cells and primary MSCs secrete substantial amount of NGF into culture medium. Error bar=SEM. *p,0.01. (C) Levels of human BDNF in ipsilateral
sections (transplanted side) of B10 cell transplanted Brain. *p,0.0001) as compared to those of PBS injected brain (undetectable) at 2, 4 and 6 weeks
post-transplantation. (D) Levels of human BDNF in ipsilateral brain sections of B10 cell transplanted side as compared to contralateral sections
without transplanted B10 cells at 2, 4 and 6 weeks post-transplantation. In the PBS injected control brain, BDNF level was undetectable. *p,0.01.
doi:10.1371/journal.pone.0001272.g011
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a regulatable tetracycline (Tet) promoter. Addition of Tet to the
medium activates the v-myc protein allowing the clonally isolated
human MSCs to proliferate rapidly while holding differentiation
essentially in abeyance; in the absence of Tet, the human MSCs
cease proliferating and proceed to differentiate into various cell
types (Manuscript in preparation).
Previous works have demonstrated that human MSCs express
genes characteristic of multilineage cell type prior to unilineage
commitment [54,55]. Rodent marrow derived-multipotent pro-
genitor cells express Oct-4 as a necessary marker for pluripotency
in stem cells [56] and Otx1/2 expressed at early stages of
neuroectoderm [1]. Human MSCs also express Oct-4 [6] and
nestin [57] as neural stem cell markers and even b-tubulin III,
a neurons specific marker and GFAP, a marker for astrocytes,
were expressed prior to undergoing differentiation [7]. Moreover,
proneural genes, Otx-1, Neurogenin 2 and Musashi 1 as well as
Oct-4 and nestin have been expressed in mRNA level in human
MSCs as reorted earlier in adult derived human MSCs [6]. In the
present study, B10 as a clonal cell line originated from a single
human MSC, expresses Oct-4 and ABCG2 as general markers for
stem cells, nestin as a neural stem cell marker, and Mash-1 and
Otx-2 which are basic helix-loop-helix (bHLH) transcription
factors important in developmental process of neurogenesis. Thus
B10 human MSC cell line has same differentiation capacity into
human neural stem cells as in primary human MSCs.
Previous studies have reported that the MSCs derived from
bone marrow differentiate into neuronal lineage cells [56,57] and
expression of b-tubulin III in early phase of neuronal differentiation
was gradually replaced by neurofilament (NF) proteins as human
MSCsbecome more mature neuronallineagecells[58,59].Increased
expression of b-tubulin III and NF-L in MSCs following bFGF
treatmentasshowninthe presentstudysuggeststhatB10differentiate
into neuronal progenitor cells and neurons via bFGF-mediated
differentiation pathway. Moreover, B10 cells expressing NF proteins
were identified to generate inward currents of voltage-activated Na+
channels, which indicate that the neuronally differentiated B10 cells
have electrophysiological characteristics of mature neurons. Further
study is necessary to characterize morphological and functional
phenotypes in these cells such as expression of neurotransmitter type
and formation of synaptic connection.
MSCs are known to show a capacity to migrate and differentiate
into various cell types, and to be integrated into the host tissues
following in vivo transplantation. Following bone marrow trans-
plantation, donor-derived cells have been found in multiple non-
hematopoietic tissues, including liver and the brain. In the brain,
grafted marrow-derived stem cells could express the neural
antigens Neu-N and nestin [15,60,61]. Previous studies have
shown that bone marrow MSCs injected intravenously or
transplanted in cerebrum significantly reduced motor and
neurological deficits in animal models of traumatic brain injury
[62], Parkinson disease [63] and brain ischemia [13–15].
In the present study, transplantation of B10 MSCs into the
ipsilateral cortex above the intracerebral hemorrhagic lesion
showed that a large number of B10 cells survive, migrate along
the boundary zones adjacent to the hemorrhage core and
differentiate into neurons and astrocytes. These observations are
consistent with the findings of previous studies that the grafted
bone marrow stem cells could differentiate into neural cells in the
microenvironment of lesioned brain [13,15]. It is evident that the
neurogenesis and migration of transplanted MSCs are influenced
by the cues or signals in the microenvironment of damaged brain.
Previous studies have shown that a limited degree of endogeneous
neurogenesis occur in damaged region, which was induced by
stroke [64,65]. Further studies are needed to determine whether
grafted B10 MSCs could integrate among the neurons of host
brain, make new synaptic connections with them and replace lost
neurons. Electrophysiological studies undergoing in our laboratory
in brain slices obtained from rat brain grafted with B10 cells so far
did not yield positive evidence of new synaptic connection.
A considerable number of the transplanted B10 migrate to the
boundary region, corpus callosum and hippocampus in the
contralateral side of transplantation and differentiate into neurons
even in far beyond hemorrhagic stroke site. In a previous study,
human neural progenitor cells integrate into hippocampus and
corpus callosum following transplantation in lateral ventricle and
striatum of neonatal and adult animals [66]. Transplanted MSCs
migrated along corpus callosum [15,67] and to hippocampus
[14,68] in normal rats or rats with ischemic lesions. Although
mechanism by which MSCs and neural stem cells migrate
extensively in selective manner to the pathological lesions is
unclear, it is suggested that the transplanted B10 cells mimic the
behavior of neural stem cells that are recruited by chemoattactant
signals produced at CNS injury sites such as cytokines including
stem cell factor (SCF) [69], stromal cell derived factor-1 (SDF-1)
[70] and vascular endothelial cell growth factor (VEGF) [71].
Other cytokines with important functions in CNS development
including basic FGF, EGF and TGFa are also shown to increase
ischemia-induced proliferation and migration of neural progenitor
cells [72]. Since B10 cells express c-kit, the receptor for SCF,
CXCR4, the receptor for SDF-1, and VEGFR1, receptor for
VEGF (Figure 10), pathways involving SCF/c-kit, SDF-1/
CXCR4 and VEGF/VEGFR are involved in the migration of
MSCs to the sites of ICH brain damage and also to corpus
callosum and hippocampus. Migration of MSCs toward sites of
brain injury may represent an adaptive response of MSCs for the
purpose of limiting tissue injury or repair the tissue damage. The
mechanism by which the B10 MSCs undergo selective and long
distance migration to non-injured sites of corpus callosum and
hippocampus might differ from that for the ICH injury and further
studies are required to identify the signal(s) for the MSC migration
to apparently normal brain region.
Brain microenvironment is important in determining survival,
migration and differentiation of exogenously transplanted pro-
genitor cells and stem cells. Following the collagenase injection
into the striatum, a profuse hemorrhage in the area caused by
blood vessels damaged by the proteinase enzyme ensues and the
hemorrhage core routinely is absorbed within a week or two, but
immune cells released from the vessels remain in the hemorrhage
core area. Transplantation of B10 human MSCs is conducted one
week after the hemorrhage lesion, thus host immune cells might
attack the newly implanted human MSCs in the area. On the
other hand, it is known that damaged brain cells and tissues of the
host are also capable of releasing molecules that stimulate
production of neurotrophic factors in transplanted MSCs [73].
In the present study, no immunosuppressant such as cyclospor-
ine A was utilized to inhibit immune reaction and promote the
long-term survival of implanted MSCs in the ICH animals. In
earlier studies we have intravenously transplanted immortalized
stable human neural stem cells in ICH and focal ischemia model
rats without administering immunosuppressant, and found a good
survival of grafted NSCs in the brain and a good functional
recovery in these animals [21–24]. However, low survival rate of
grafted B10 cells in ICH mice as demonstrated in the present study
is a grave concern. The survival rate of transplanted B10 cells at 2
weeks post-transplantation is 41% (52% with correction) and that
of 6 weeks is 20% (25% with correction). Obvious cause for such
poor survival rate of human MSCs in experimental animals is
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attacked and destroyed. For that reason, we have to employ
immunosuppressants in our future studies to protect grafted
human MSCs from cell death in experimental animals. It should
be noted that the immunosuppressant cyclosporine has recently
been demonstrated to exert neuroprotection in experimental
stroke among other disease models [74–76].
The importance of immunosuppresion in the event of clinical
trials using human MSCs in patients suffering from stroke or other
neurological diseases is well recognized. Immunological rejection
of neural transplants poses a significant problem to be overcome in
order to conduct successfully stem cell-based cell therapy in
human patients. A previous study has suggested that the use of
progenitors and stem cells for neural grafting is more promising, as
these could be maintained in vitro until use, and evoke less
immunogenic responses when compared to primary grafts;
implantation of immortalized mouse neural stem cells in rat
ischemia model has resulted in a good survival at 2 weeks post-
transplantation in the absence of immune reaction caused by
grafted cells [77]. Further investigations into the specific
mechanisms underlying drug actions of immunosuppressants in
experimental stroke will certainly improve the therapeutic
potential of these drugs for stem cell-based cell therapy.
Endogeneous or exogenously injected neurotrophic factors
including BDNF, GDNF, CNTF and NT3 had neuroprotective
effect in damaged brain including stroke [78–80]. Extracts from
ischemic rat brain have induced the production of BDNF, bFGF,
VEGF and HGF in human MSCs in culture [73]. In addition,
mouse MSCs are shown to express VEGFa and EGF in cDNA
microarray analysis [81]. A recent study has also reported that
transplanted porcine choroids plexus in microcapsules improved
behavioral performance and decreased the pathological lesion size
in rat ischemia stroke model by producing several trophic factors
including NGF, BDNF and GDNF [82].
Our RT-PCR studies show that B10 human MSCs as in
primary human MSCs express BDNF, GDNF, CNTF, bFGF,
VEGF, HGF and IGF that may work as neuroprotective factors in
the ICH mice. B10 MSCs secrete both NGF and BDNF proteins
in higher concentrations in vitro and in vivo than primary human
MSCs. Recent studies have shown that the intracerebral injection
of MSCs transfected with the BDNF or GDNF gene resulted in
improved function and reduced ischemic damage in a rat stroke
model of middle cerebral artery occlusion [83]. In the present
study, grafted B10 cells located in peri-hemorrhagic lesion sites
express strong BDNF activity, which indicate that the grafted B10
cells secrete BDNF neurotrophic factor in the microenvironment
of ICH and promote survival of host neurons and functional
recovery of ICH animals.
As for the parameters in evaluation of treatment efficacy in stem
cell-based cell therapy for stoke animal models, several parameters
such as improvement in behavior, number of cells differentiating
into neurons, degree of cellular migration and number of surviving
cells in the graft, could be considered. From the results described
in the present study and our previous studies in animal models of
stroke with transplantation of immortalized human neural stem
cells [20–24], two parameters, behavioral recovery and survival of
grafted cells, have paramount importance. Without behavioral
improvement following cell therapy with stem cells, the study in
question is a total failure, and no behavioral improvement could
be expected in the absence of good survival in grafted cells.
In conclusion, B10 human MSC cell line can be induced to
differentiate mostly into neurons and smaller number of astrocytes
in vitro and in vivo and has a potential to produce a number of
neuroprotective factors including NGF and BDNF. The present
study demonstrates that B10 human MSC cell line is not only
a useful tool for the studies of organogenesis and specifically for the
neurogenesis, but also as a renewable cell source for cell therapy
studies in animal models of stroke and other neurological
disorders.
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